Page 261 - The Vasculitides Volumes 2

Overview of the Treatment of Primary Systemic Vasculitis 237

[10] Merkel, P. A., Aydin, S. Z., Boers, M., et al. The OMERACT core set of outcome
measures for use in clinical trials of ANCA-associated vasculitis. J. Rheumatol. 2011;
38: 1480-1486.

[11] Hatemi, G., Merkel, P. A., Hamuryudan, V., et al. Outcome measures used in clinical
trials for Behçet syndrome: a systematic review. J. Rheumatol. 2014; 41:599-612.

[12] Hellmich, Flossmann O., Gross, W., et al. EULAR recommendations for conducting
clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil
cytoplasm antibody-associated vasculitis. Ann. Rheum. Dis. 2007; 66:605-617.

[13] Hogan, S., Falk, R., Chin, H., et al. Predictors of relapse and treatment resistance in
patients with antineutrophil cytoplasmic antibody-associated small-vessel vasculitis.
Ann. Intern. Med. 2005; 143:621-631.

[14] Specks, U., Merkel, P. A., Seo, P., et al., for RAVE-ITN Research Group. Efficacy of
remission-induction regimens for ANCA-associated vasculitis. N. Engl. J. Med. 2013;
369:417-427.

[15] Guillevin, L., Lhote, F., Gayraud, M., et al. Prognostic factors in polyarteritis nodosa
and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine
(Baltimore) 1996; 75:17-28.

[16] Guillevin, L., Pagnoux, C., Seror, R., et al. The Five-Factor Score revisited: assessment
of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study
Group (FVSG) cohort. Medicine (Baltimore) 2011; 90:19-27.

[17] Gayraud, M., Guillevin, L., le Toumelin, P., et al. Long term followup of polyarteritis
nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four
prospective trials including 278 patients. Arthritis and Rheum. 2001; 44:666-675.

[18] Ribi, C., Cohen, P., Pagnoux, C., et al. Treatment of Churg-Strauss syndrome without
poor-prognosis factors: a multicenter, prospective, randomized open-label study of
seventy-two patients. Arthritis Rheum. 2008; 58:586-594.

[19] Cohen, P., Pagnoux, C., Mahr, A., et al. Churg-Strauss syndrome with poor-prognostic
factors: A prospective multicenter trial comparing glucocorticoids and six or twelve
cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007; 57:686-693.

[20] Guillevin, L., Cohen, P., Mahr, A., et al. Treatment of polyarteritis nodosa and
microscopic polyangiitis with poor prognoses factors: A prospective trial comparing
glucocorticoids and six or twelve cyclophosphamide pulses in six-five patients.
Arthritis Rheum. 2003; 49:93-100.

[21] Ribi, C., Cohen, P., Pagnoux, C., et al. Treatment of polyarteritis nodosa and
microscopic polyangiitis without poor-prognostic factors: A prospective randomized
study of one hundred twenty-four patients. Arthritis Rheum. 2010; 62:1186-1197.

[22] Walsh, M., Merkel, P. A., Mahr, A., Jayne, D., Effects of duration of glucocorticoid
therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A
meta-analysis. Arthritis Care Res. 2010; 62:1166-1173.

[23] McGregor, J. G. Hogan, S. L., Hu, Y., et al. Glucocorticoids and relapse and infection
rates in anti-neutrophil cytoplasmic antibody disease. Clin. J. Am. Soc. Nephrol. 2012;
7:240-247.

[24] Fauci, A. S., Wolff, S. M. Wegener?s granulomatosis: Studies in eighteen patients and a
review of the literature. Medicine (Baltimore) 1973; 52:535-561.

Complimentary Contributor Copy